Press Releases | Pfizer

Skip to main content

Science
Products
Stories
Newsroom
About

Investors Careers Media Partners

Careers
Investors

How can we help you?

4592 search results for

Suggestions within Pfizer.com

Home

Newsroom

Press Releases

Press Releases

Year

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate

Financial

Prescription Medicines

Research and Pipeline

Social Responsibility

Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

March 2023

03.14.2023 VaccinesCovid-19Vaccines Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
03.01.2023 VaccinesCovid-19Vaccines Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years

February 2023

02.24.2023 VaccinesCovid-19Vaccines Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster
02.21.2023 VaccinesVaccines U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

December 2022

12.28.2022 VaccinesVaccines U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
12.07.2022 VaccinesVaccines U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
12.05.2022 VaccinesCovid-19 Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
12.01.2022 VaccinesResearchVaccines Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

November 2022

11.18.2022 VaccinesCovid-19Vaccines Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
11.10.2022 VaccinesCovid-19Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

October 2022

10.13.2022 VaccinesVaccines Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
10.12.2022 VaccinesCovid-19Vaccines Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Current page 1
Page 2
Page 3

Investors
Careers
Media
Partners

Grant Seekers
Healthcare Professionals
Business to Business
Merchandise

Privacy Statement
Terms of Use
Contact Us

© 2023 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube